These specific activities of DCs are referred to as cross-presentation (CP), and play a definitive role in initiating CD8+ T cell-induced immune responses against cancer and/or viruses (cross-priming) or to induce peripheral tolerance (cross-tolerance) [4,5,6,7,8]. The gene discussed is CD8A; the disease is cancer.